Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2021.113923
Abstract: Dolutegravir, raltegravir and darunavir are three antiretroviral drugs widely used in combined antiretroviral therapies. These three drugs are highly bound to plasma proteins. Compared to the total concentration, the concentration of unbound drug which is… read more here.
Keywords: raltegravir; dolutegravir; plasma; ultrafiltration ... See more keywords
A safety evaluation of raltegravir for the treatment of HIV
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1411903
Abstract: ABSTRACT Introduction: Raltegravir (RAL) was the first commercialized agent from a new drug class with an innovative target, the integrase. Since its introduction in clinical practice RAL has become widely used for the treatment of… read more here.
Keywords: treatment; treatment hiv; safety; safety evaluation ... See more keywords
Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkw375
Abstract: Objectives A low CD4/CD8 ratio during treated HIV identifies individuals with heightened immunoactivation and excess mortality. Whether ART regimens elicit distinct CD4/CD8 ratio recovery remains unknown. We aimed to compare the efficacy of an integrase… read more here.
Keywords: cd4 cd8; cd8 ratio; versus; normalization ... See more keywords
Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens
Sign Up to like & getrecommendations! Published in 2018 at "AIDS"
DOI: 10.1097/qad.0000000000001668
Abstract: Objective: To explore the effectiveness of raltegravir-based antiretroviral therapy (ART) on treatment response among ART-naive patients seeking routine clinical care. Design: Cohort study of adults enrolled in HIV care in the United States. Methods: We… read more here.
Keywords: count recovery; suppression; treatment; cell count ... See more keywords
Switch from tenofovir DF to raltegravir is not associated with weight gain over 96 weeks.
Sign Up to like & getrecommendations! Published in 2019 at "AIDS"
DOI: 10.1097/qad.0000000000002473
Abstract: : Integrase inhibitor-based antiretroviral therapy (INSTI-ART) can cause weight gain. It is unknown if this is a class effect, with limited data regarding raltegravir. In 37 virologically suppressed adults (36 men, mean age 49 years)… read more here.
Keywords: raltegravir associated; tenofovir raltegravir; raltegravir; weight gain ... See more keywords
Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report
Sign Up to like & getrecommendations! Published in 2022 at "Antiviral Therapy"
DOI: 10.1177/13596535221119932
Abstract: We report a case of an infant with HIV receiving raltegravir granules for oral suspension and rifampicin-based TB prophylaxis. Raltegravir trough levels remained subtherapeutic and viral load increased during concurrent rifampicin therapy despite using double-dosed… read more here.
Keywords: infant hiv; report; case; raltegravir ... See more keywords
Real-World Characterization of the Portuguese Population Living with HIV who Initiated Raltegravir Based-Regimens: The REALITY Study.
Sign Up to like & getrecommendations! Published in 2022 at "Acta medica portuguesa"
DOI: 10.20344/amp.16785
Abstract: INTRODUCTION Although raltegravir has been available since 2007, data are lacking on the Portuguese population living with HIV who initiated this antiretroviral therapy. Hence, this study aimed to characterize the patients who initiated raltegravir-based regimens between January… read more here.
Keywords: based regimens; hiv; raltegravir; treatment ... See more keywords
Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2019.00903
Abstract: Raltegravir, an inhibitor of human immunodeficiency virus-1 (HIV-1) integrase, has been used to treat HIV/acquired immunodeficiency syndrome; however, its therapeutic effects on pulmonary fibrosis have not been investigated. In this study, the in vitro effects… read more here.
Keywords: raltegravir; fibrosis; pulmonary fibrosis; vitro vivo ... See more keywords